Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

50%

5 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

5(62.5%)

N/A

2(25.0%)

Phase 2

1(12.5%)

8Total

Phase 4(5)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT04481555Phase 4Completed

Eosinophil-guided Reduction of Inhaled Corticosteroids

Role: lead

NCT04538976Phase 4Completed

Copd Exacerbation and Pulmonary Hypertension Trial

Role: lead

NCT05563675Phase 4Completed

Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause

Role: lead

NCT05344300Unknown

Temperature Recording in Lungs of Volunteers With and Without Pulmonary Diseases

Role: lead

NCT05351242Not ApplicableRecruiting

Thermotherapy Against Persistent Bacterial LUNG Infections

Role: lead

NCT03262142Phase 4Terminated

Targeted AntiBiotics for Chronic Pulmonary Diseases

Role: lead

NCT04216277Not ApplicableWithdrawn

The Procalcitonin Guided Antibiotics in Respiratory Infections in General Practice

Role: lead

NCT04322396Phase 2Terminated

Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19

Role: lead

NCT03140761Completed

The Prevalence of Secondary Adrenal Insufficiency in Patients With Exacerbation of COPD in Glucocorticoid Treatment Related to Differenct Gene Polymorphisms of the Glucocorticoid Receptor Gene

Role: lead

NCT02857842Phase 4Completed

Corticosteroid Reduction in COPD

Role: lead

All 10 trials loaded